NFKB1 and breast carcinoma: It is known that a sustained, constitutive activation of NFκB contributes to malignant progression and therapeutic resistance in most of the major forms of human cancer, such as human lymphomas [60], carcinomas of the breast [126], prostate [127], lung [128], colon [129], pancreas [130], thyroid [131], head and neck [132] and cervix [133].